[ad_1] SHANGHAI, Nov. 29, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines,…
Tag: Nephropathy
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
[ad_1] –Nefecon® is the first approved medicine with an IgAN indication in China— –The approval marks a new era of IgAN treatment for Chinese patients– SHANGHAI, Nov. 23, 2023 /PRNewswire/…
IgA Nephropathy (IgAN) Epidemiology Forecast Report 2019-2023 & 2023-2032: Focus on 8 Major Markets – United States, Germany, Spain, Italy, France, United Kingdom, Japan, and China – ResearchAndMarkets.com
[ad_1] IgA Nephropathy (IgAN) Epidemiology Forecast Report 2019-2023 … WV News [ad_2] Source link
Everest Medicines Announces New Drug Application Acceptance by Singapore HSA for Nefecon for the Treatment of Primary IgA Nephropathy
[ad_1] Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023 SHANGHAI, April 5, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or…